Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma

Journal of Clinical Oncology

Volumn 16, Issue 11, 1998, Pages 3584-3591

  Karjalainen, Jari M ^a   Kellokoski, Jari K ^a   Eskelinen, Matti J ^a   Alhava, Esko M ^a   Kosma, Veli Matti ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P21; TRANSCRIPTION FACTOR AP 2;

ADULT; ARTICLE; BLEEDING; CANCER STAGING; CANCER SURVIVAL; DATA ANALYSIS; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MELANOMA; PREDICTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SURVIVAL RATE; TUMOR GROWTH; TUMOR RECURRENCE;

EID: 0031763526     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.11.3584     Document Type: Article

References (50)

1. Brach M, Kauer M, Friedhelm H: Contribution of transcription factors to oncogenesis. Cytokines Mol Ther 2:81-87, 1996 (review)
2. Mitchell PJ, Timmons PM, Hebert JM, et al: Transcription factor AP-2 is expressed in neural crest cell lineages during mouse embryogenesis. Genes Dev 5:105-119, 1991
3. Williams T, Admon A, Luscher B, et al: Cloning and expression of AP-2, a cell-type-specific transcription factor that activates inducible enhancer elements. Genes Dev 2:1557-1569, 1988
4. Imagawa M, Chiu R, Karin M: Transcription factor AP-2 mediates induction by two different signal-transduction pathways: Protein kinase C and cAMP. Cell 51:251-260, 1987
5. Zeng Y-X, Somasundaram K, El-Deiry WS: AP2 inhibits cancer cell growth and activates p21/WAF1/CIP1 expression. Nat Genet 15:78-82, 1997
6. Bar-Eli M: Molecular mechanisms of melanoma metastasis. J Cell Physiol 173:275-278, 1997
7. Sers C, Kirsch K, Rothbacher U, et al: Genomic organization of the melanoma-associated glycoprotein MUC18: Implications for the evolution of the immunoglobulin domains. Proc Natl Acad Sci USA 90:8514-8518, 1993
8. Huhtala P, Chow LT, Tryggvason K: Structure of the human type IV collagenase gene. J Biol Chem 265:11077-11082, 1990
9. Bosher JM, Williams T, Hurst HC: The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. Proc Natl Acad Sci USA 92:744-747, 1995
10. Hennig G, Behrens J, Truss M, et al: Progression of carcinoma cells is associated with alterations in chromatin structure and factor binding at the E-cadherin promoter in vivo. Oncogene 11:475-484, 1995
11. Hennig G, Löwrick O, Birchmeier W, et al: Mechanisms identified in the transcriptional control of epithelial gene expression. J Biol Chem 271:595-602, 1996
12. Leask A, Byrne C, Fuchs E: Transcription factor AP-2 and its role in epidermal-specific gene expression. Proc Natl Acad Sci USA 88:7948-7952, 1991
13. Snape AM, Winning RS, Sargent TD: Transcription factor AP-2 is tissue-specific in Xenopus and is closely related or identical to keratin transcription factor 1 (KTF-1). Development 113:283-293, 1991
14. Byrne C, Fuchs E: Probing keratinocyte and differentiation specificity of the human K5 promoter in vitro and in transgenic mice. Mol Cell Biol 13:3176-3190, 1993
15. Schorle H, Meier P, Buchert M, et al: Transcription factor AP-2 essential for cranial closure and craniofacial development. Nature 381:235-238, 1996
16. Zhang J, Hagopian-Donaldson S, Serbedzija G, et al: Neural tube, skeletal and body wall defects in mice lacking transcription factor AP-2. Nature 381:238-241, 1996
17. Gaynor RB, Muchard C, Xia Y, et al: Localization of the gene for the DNA-binding protein AP-2 to human chromosome 6p22.3-pter. Genomics 10:1100-1102, 1991
18. Foulkes WD, Ragoussis J, Stamp GWH, et al: Frequent loss of heterozygosity on chromosome 6 in human ovarian carcinoma. Br J Cancer 67:551-559, 1993
19. Robertson GP, Coleman AB, Lugo TG: Mechanisms of human melanoma cell growth and tumor suppression by chromosome 6. Cancer Res 56:1635-1641, 1996
20. Trent JM, Stanbridge EJ, McBride HL, et al: Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6. Science 247:568-571, 1990
21. Natali PG, Nicotra MR, Winkler AB, et al: Progression of human cutaneous melanoma is associated with loss of expression c-KIT proto-oncogene receptor. Int J Cancer 52:197-201, 1992
22. Lassam N, Bickford S: Loss of c-KIT expression in cultured melanoma cells. Oncogene 7:51-56, 1992
23. Zakut R, Perils R, Eliyahu S, et al: KIT ligand (mast cell growth factor) inhibits the growth of c-KIT-expressing melanoma cells. Oncogene 8:2221-2229, 1993
24. Gutman M, Singh R, Radinsky R, et al: Intertumoral heterogeneity of receptor-tyrosine kinases expression in human melanoma cell lines with different metastatic capacities. Anticancer Res 14:1759-1766, 1994
25. Jiang H, Lin J, Su ZZ, et al: The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells. Oncogene 10:1855-64, 1995
26. Vidai MJ, Loganzo F Jr, de Oliveira AR, et al: Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas. Melanoma Res 5:243-50, 1995
27. Maelandsmo GM, Holm R, Fodstad O, et al: Cyclin kinase inhibitor p21/WAF1/CIP1 in malignant melanoma: Reduced expression in metastatic lesions. Am J Pathol 149:1813-22. 1996
28. Chen I-T, Smith ML, O'Connor PM, et al: Direct interaction of Gadd45 with PCNA and evidence for competitive interaction of Gadd45 with p21/WAF-1/CIP1 with PCNA. Oncogene 11:1931-1937, 1995
29. Hiyama H, Iavarone A, LaBaer J, et al: Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression. Oncogene 14:2533-2542, 1997
30. Hermanek P, Sobin LH (eds): UICC International Union Against Cancer: TNM Classification of Malignant Tumours (ed 4, rev 2). Berlin, Germany, Springer-Verlag, 1992, pp 99-101
31. Breslow A: Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 12:902-908, 1970
32. Clark WH Jr, From L, Bernardino EA, et al: The histogenesis and biologic behaviour of primary human malignant melanomas of the skin. Cancer Res 29:705-726, 1969
33. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
34. Cox DR: Regression models and life tables with discussion. J Stat Soc B 34:187-192, 1972
35. Hietala KA, Kosma V-M, Syrjänen KJ, et al: Correlation of MIB-1 antigen expression with transcription factors Skn-1. Oct-1, AP-2, and HPV type in cervical intraepithelial neoplasia. J Pathol 183:305-310, 1997
36. Buettner R, Kannan P, Imhof A, et al: An alternatively spliced mRNA from the AP-2 gene encodes a negative regulator of transcriptional activation by AP-2. Mol Cell Biol 13:475-480, 1993
37. Mitchell PJ, Wang C, Tjian R: Positive and negative regulation of transcription in vitro: Enhancer-binding and protein AP-2 is inhibited by svT4 antigen. Cell 50:847-861, 1987
38. Mori N, Prager D: High levels of AP-2-binding activity in cell lines infected with human T-cell leukemia virus type I: Possible enhancement of AP-2 binding by human T-cell leukemia virus type I tax. Cancer Res 56:779-782, 1996
39. Muchardt C, Seeler J-S, Nirula A, et al: Transcription factor AP-2 activates gene expression of HTLV-I. EMBO J 11:2573-2581, 1992
40. Mercurio F, Karin M: Transcription factors AP-3 and AP-2 interact with the SV40 enhancer in a mutually exclusive manner. EMBO J 8:1455-1460, 1989
41. Royer HD, Freyaldenhoven MP, Napierski I, et al: Delineation of human papillomavirus type 18 enhancer binding proteins: The intracellular distribution of a novel octamer binding protein p92 is cell cycle regulated. Nucleic Acids Res 19:2363-2371, 1991
42. Borg A, Baldetorp B, Ferno M, et al: ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81:137-144, 1994
43. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
44. Tetu B, Brisson J: Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 73:2359-2365, 1994
45. Lehmann JM, Holzmann B, Breitbart EW, et al: MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecule of the immunoglobulin superfamily. Cancer Res 47:841-845, 1989
46. Luca M, Hunt B, Bucana CD, et al: Direct correlation between MUC18 expression and metastatic potential of human melanoma cells. Melanoma Res 3:35-41, 1993
47. Bosher JM, Totty NF, Hsuan JJ, et al: A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Oncogene 13:1701-1707, 1996
48. Buzaid AC, Ross MI, Balch CM, et al: Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 15:1039-1051, 1997
49. Balch C: Cutaneous melanoma: Prognosis and treatment results worldwide. Semin Surg Oncol 8:400-414, 1992
50. Vollmer R: Malignant melanoma. A multivariate analysis of prognostic factors. Pathol Annu 24:383-407, 1989